In 2026, new guidelines were released by the American Heart Association and the American College of Cardiology to help manage dyslipidemia, a condition where people have high levels of cholesterol or fatty acids in their blood. Dyslipidemia affects at least a quarter of Americans and can lead to atherosclerotic cardiovascular disease (ASCVD), a group of conditions caused by plaque buildup in blood vessels, which can result in heart attacks or strokes. These updated guidelines replace the previous 2018 recommendations and offer more detailed strategies for treating and preventing this condition. The new guidelines stress the importance of earlier and more aggressive treatment for high cholesterol and fatty acids, especially in younger individuals. This shift is based on research showing that the longer someone has high cholesterol, the higher their risk of developing cardiovascular disease over their lifetime. Doctors are now encouraged to use advanced blood tests and imaging tools to better assess a patient's risk. These tests include standard lipid tests, like measuring levels of "bad" LDL cholesterol and "good" HDL cholesterol, as well as newer tests for lipoprotein A (LpA) and apolipoprotein B (ApoB). The guidelines also recommend checking coronary artery calcium (CAC) levels, which provide a direct measure of calcium buildup in the heart's arteries. To help doctors determine a patient's risk, the guidelines introduce a tool called PREVENT-ASCVD. This online calculator uses factors such as body mass index, blood pressure, diabetes history, kidney function, and smoking status to estimate a person's risk of cardiovascular disease over 10 and 30 years. Based on this risk assessment, doctors can choose from several newer medications to treat high cholesterol, including statins like atorvastatin and rosuvastatin, which remain the standard treatment. Additional medications may be prescribed if statins are not effective or cause side effects. The guidelines highlight the importance of personalized treatment plans. While traditional markers like LDL cholesterol remain key, newer biomarkers such as ApoB and LpA can offer a more complete picture of a person’s risk, especially for those with diabetes or high triglyceride levels. ApoB measures the number of plaque-forming particles in the blood, while LpA, which has a stickier protein, can increase the risk of artery blockages. Coronary artery calcium scores, obtained through CT scans, also play a role in assessing risk and guiding treatment decisions. In addition to medication, the guidelines emphasize lifestyle changes such as reducing sugar, refined carbohydrates, saturated fats, and alcohol intake. They recommend 150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous activity, along with two days of resistance training. Weight loss of 5% to 10% for overweight or obese individuals is also encouraged. The new guidelines promote earlier screening, with children aged 9 to 11 having their cholesterol levels checked and adults starting regular screenings at age 19. This shift toward personalized and proactive care aims to reduce the risk of cardiovascular disease across a person's lifetime.